When Andrew von Eschenbach was coaxed to come over from NCI to lead FDA, he seemed like a perfect choice to right the ship and manage FDA through the final years of the Bush Administration. But, as the hoopla over Avandia shows, the ship is still taking on water. The commissioner’s tone and vision aren’t helping.
By Ramsey Baghdadi
There was a telling exchange between Food & Drug Administration commissioner Andrew von Eschenbach and Massachusetts Democrat John Tierney during...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
